Dermatology

Half of all cases of vitiligo occur in childhood, and accessibility to therapy has been an ongoing issue.

Data from the ADQoC Initiative show that patients with AD are often misdiagnosed or the severity of their disease was undertreated.

Dr. Amy Paller and colleagues noted high efficacy rates and minimal adverse events from biologic therapy.

Investigators suggested systemic mental health monitoring could be beneficial for women who have atopic disease before pregnancy.

Investigators called for more studies which feature adequately powered trials of test-guided dietary exclusions.

The topical drug was associated with adverse events that were mainly localized to the application site and mild to moderate in nature.

According to investigators, no previous studies had investigated the expression of IL-38 in patients with vitiligo.

A litany of research has begun to shape the potential benefit of UV treatment for the skin disorder. Experts share what more needs to be known.

Nearly 70% of all vitiligo patients included in the study remained pigmented after systemic immunomodulatory treatment, with no evidence of recurrence of the disease.

To the investigators’ knowledge, the study offers insights into lesion presentations on undiagnosed adults with vitiligo.

Investigators said that patient-reported outcomes from the 2 abrocitinib groups showed greater efficacy than the dupilumab and placebo groups.

Respondents suggested that increasing product availability and demonstrating the consequences of sunburn could increase sun protection among young people.

Dr. Elewski hopes that in the future more clinicians will prescribe biologics such as secukinumab and etancercept for the treatment of psoriasis.

Though Dr. Khattri felt the diagnosis of psoriatic arthritis had been “stagnant”, the inclusion of biologic therapies and more has been a welcomed change.

Certain biologics such as infliximab have aided psoriasis patients in the mitigation of symptoms from the COVID-19 virus.

Dr. Desai says that Janus kinase inhibitors present a new mechanism of action, with effects on cytokine signals that signal inflammation in atopic diseases.

Swanson noted the efficacy and safety of dupilumab, which she feels revolutionized patient care.

Dr. Khattri speaks of the benefits of diagnosing the condition early in psoriasis patients, as well as what dermatologists can do before referring a patient to a rheumatologist.

New therapies are breaking ground in the world of vitiligo research, which Dr. Desai believes will result in FDA approvals in the coming years.

The study used deep phenotyping to identify several factors in adults and adolescents with the disease.

The interactive map offers patients insights into all available treatments for vitiligo as well as coping strategies.

Dr. Arianna Yanes provides insights into 7 new handouts developed by the Society for Pediatric Dermatology and how they aid nurses and teachers in creating a more inclusive setting for children with skin conditions

Year-long treatment with the biologic resulted in significant improvements in patient perception of well-being and treatment effect.

An assessment of data from the DISCOVER and VOYAGE trials show the IL-23 inhibitor provides similar safety profiles in patients with either psoriatic disease.

Investigators collected data from 5 focus groups of community-based pediatricians to address ongoing concerns on the treatment of atopic dermatitis in this pediatric population.

Over half of all patients in the study had achieved an EASI-75 within a year, and investigators noted that patient and family satisfaction with the MADP program was high.

Investigators report that the skin condition mediated the association between a a interleukin-4 receptor agonist variant and food allergy.

Investigators report that 21.9% of all participants with allergic contact dermatitis had 1 or more currently relevant reactions to a supplemental allergen/substance.

Investigators wrote that the phenomena can be used to evaluated clinical features of the disease, resulting in more precise therapy recommendations.

By identifying 22 key parameters in study designs, investigators hope to establish a standardized approach for analyzing moderate-to-severe atopic dermatitis trial results.